No Picture
News

Odyssey Group International, Inc. Provides Notice of Annual Meeting of Stockholders

IRVINE, CA, July 26, 2021 (GLOBE NEWSWIRE) —  Odyssey Group International, Inc. (OTCQB: ODYY) (“ODYY” or “the Company”), Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on… […]

No Picture
News

Bayer poaches newest early R&D head from Roche; GlaxoSmithKline earns expanded nod for Shingrix

Bayer has plucked its new head of research and early development from Roche’s pRED organization, where he was doing much the same thing before making the leap. The German pharma company announced this morning that it had signed up Dominik Ruettinger fo… […]

No Picture
News

Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease

SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)– #ASCRS2021–Allegro Ophthalmics announces positive results of ex-U.S. Phase 2 trial of ALG-1007 for the treatment of dry eye disease; FDA acceptance of IND. […]

No Picture
News

ImmixBio Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

LOS ANGELES: LOS ANGELES, July 23, 2021 /PRNewswire/ — Immix Biopharma, Inc. today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to … […]

No Picture
News

ImaginAb Announces Extension Of Long-Standing Partnership With Boehringer Ingelheim

LOS ANGELES: LOS ANGELES, July 23, 2021 /PRNewswire/ — ImaginAb Inc, a market leading global biotechnology company, focused on developing next generation immuno oncology imaging agents and therapeutic radiopharmaceuticals (RPT), today announced the si… […]

No Picture
Nasdaq:OPNTUS6837501039

Opiant Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

SANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial res… […]